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In this study, 4,7-dimethoxy-5-methyl-l,3-benzodioxole (SY-1) was isolated from three diﬀerent sources of dried fruiting bodies
of Antrodia camphorate (AC). AC is a medicinal mushroom that grows on the inner heartwood wall of Cinnamomum kanehirai
Hay (Lauraceae), an endemic species that is used in Chinese medicine for its anti-tumor and immunomodulatory properties. In
this study, we demonstrated that SY-1 profoundly decreased the proliferation of human colon cancer cells (COLO 205) through
G0/G1 cell-cyclearrest(50–150μM)andinductionofapoptosis(>150μM).Cell-cycle arrestinduced by SY-1wasassociatedwitha
signiﬁcantincreaseinlevelsofp53,p21/Cip1 andp27/Kip1,andadecrease incyclinsD1,D3andA.Incontrast,SY-1treatmentdid
not induce signiﬁcant changes in G0/G1 phase cell-cycle regulatory proteins in normal human colonic epithelial cells (FHC). The
cellswerecultured insoftagartoevaluateanchorage-independentcolonyformation,andwefoundthatthenumberoftransformed
colonies was signiﬁcantly reduced in the SY-1-treated COLO 205 cells. These ﬁndings demonstrate for the ﬁrst time that SY-1
inhibits human colon cancer cell proliferation through inhibition of cell growth and anchorage-independent colony formation in
soft agar. However, the detailed mechanisms of these processes remain unclear and will require further investigation.
1.Introduction
Antrodia camphorata (A. camphorate, AC), also called A. cin-
namomea, is composed of fruiting bodies, mycelium and
spores. It is a parasitic fungus that only grows on the
inner heartwood wall of Cinnamomum kanehirai Hay (Lau-
raceae). AC has been used in traditional Chinese medicine
to treat food and drug intoxication, diarrhea, abdominal
pain, hypertension, pruritis (skin itch) and liver cancer;
however, its biological activities have not been meaningfully
investigated to date. Recent studies have demonstrated that
AC induces signiﬁcant apoptosis of HL-60 leukemia cells but
not of cultured human endothelial cells [1]. Another study
demonstrated that AC extracts may be used as an adjuvant
anti-tumor agent for human hepatoma cells (C3A and
PLC/PRF/5), which are resistant to most other anti-tumor
agents. Anti-tumor eﬀects were assessed by monitoring
tumor growth and the survival rate of xenograft nude mice
after combined therapy with several anti-tumor agents [2].
Colon cancer aﬀects 50–60 of every 100000 people in
North America and is the second most common cause of
cancer-related death, after lung cancer [3]. The current set
of options for treating human colon cancer are limited to
surgical resection, general chemotherapy, gene therapy and
radiation therapy [4–6]. Therefore, investigators continue
to search for new therapeutic strategies such as adjuvant2 Evidence-Based Complementary and Alternative Medicine
therapies [7]. One approach, as explored in this study,
seeks to identify medicinal agents that are capable of
arrestingthecellcycleand/oractivatingthecellularapoptotic
responseincancerouscells.Ourresultsdemonstratethat4,7-
dimethoxy-5-methyl-l,3-benzodioxole (SY-1), isolated from
dried fruiting body samples of AC, signiﬁcantly inhibited
the proliferation of COLO 205 cells through G0/G1 cell-
cycle arrest and apoptosis. We show that SY-1 inhibits
the anchorage-independent proliferation of human COLO
205 tumor cells in soft agar colony formation assays. Our
results highlight the molecular mechanisms of the anti-
tumor eﬀects as mediated by SY-1.
2.Materialsand Methods
2.1. Source of Organism. As shown in Figure 1(a), fruiting
body samples were obtained from three diﬀerentAC sources.
Sample a, designated YS-187, was a gift from Yusheng Co.,
Ltd (Taichung, Taiwan). Sample b was purchased from
Shinyi, Nantou County, Taiwan. Sample c, a strain of the
fungus A. camphorota (BCRC-36795), was purchased from
the Food Industry Research and Development Institute
(FIRDI), HsinChu County, Taiwan.
2.2. Plate Cultivation of AC. AC (BCRC-36795) was inocu-
lated in a culture medium of potato dextrose agar composed
of 0.4% diced potato extract, 2% glucose and 1.5% agar in
distilled water. The whole medium was shaken at 28 ± 1◦C
in darkness, using a 100-rpm rotary shaker for 14 days. The
culture broth was collected and evaporated under reduced
pressure. The precipitated residue (fruiting body samples of
AC) was lyophilized at −80◦C.
2.3. Isolation and Characterization of SY-1 from Fruiting Body
Samples of AC. The dried fruiting body samples (sample
b, BCRC-36795) were ground into a ﬁne powder with an
electrical mill and sequentially extracted with ethyl acetate at
80◦C under reﬂux for 3h. The methanol extracts were sepa-
rated by gel ﬁltration and chromatographed on a Sephadex
LH-20 column (MeOH). The ﬂow rate was 0.5mLmin−1.
Eachfractionmeasured15mLandwascollectedbyafraction
collector. The fractions were further analyzed using a reverse
phase C18 column (Mightysil RP-18 GP 250-10, 5μM). The
mobile phase, at a ﬂow rate of 1.5mLmin−1, consisted of
2% acetic acid and acetonitrile, programmed as follows:
2% acetic acid–acetonitrile (38:62) for 25min, decreased
to 2% acetic acid–acetonitrile (0:100) between the 26th
and 55thmin, then increased again to 2% acetic acid–
acetonitrile (38:62) between the 56th and 70thmin. The
spectrophotometric detector was set at 252nm. Retention
fractions were collected at 29.85min and concentrated by
evaporation under reduced pressure. Our results revealed
that the yields of SY-1 from dried fruiting body samples a, b
and c were 2.5, 0.415 and 5.7mg g−1, respectively. The same
fractions were lyophilized to obtain SY-1 (Figure 1(b)). The
NMR data of SY-1 is shown as follows: 1H NMR (200MHz,
CDCl3): δ 2.15 (3H, s, CH3), 3.82 (3H, s, OCH3), 3.85 (3H,
s, OCH3), 5.91 (2H, s, O–CH2–O), 6.27 (1H, s, aromatic H).
13CN M R( 5 0M H z ,C D C l 3): δ 15.92 (CH3); 56.85 (OCH3);
59.94 (OCH3); 101.44 (O–CH2–O); 108.72; 123.66; 134.63;
136.51; 138.64; 138.83. MS (M+) m/z 196. Anal. (C10H12O4)
C, H.
2.4. Cell Lines, Cell Culture and Cell Growth Curves. The HT
29(p53His273mutant)[8]andCOLO205(p53wildtype)[9]
cell lines were isolated from human colon adenocarcinomas
(HSY-1-38 and CCL-222; American Type Culture Collec-
tion). The Hep G2 (p53 wild type, ATCC HB-8065) and
MDA-MB-231 (mutant p53, ATCC HTB 26) cell lines were
derived from a human hepatocellular carcinoma and human
mammary gland epithelial adenocarcinoma, respectively [9–
12]. The oral squamous cell carcinoma cell line (Ca9-22),
bearing a mutant p53 gene, was used as a research model
[13]. FHC (CRL-1831; American Type Culture Collection)
is a cell line derived from long-term epithelial cell cultures of
normal human fetal colonic mucosa [14]. A total of 1 × 104
cells were seeded in a 35mm Petri dish and treated with SY-1
(75–375μM) for cell growth proliferation assays.
2.5. Determination of Cell Viability. After treatment with SY-
1, cell growth curves were determined at the indicated time
points with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) assay.
2.6. Flow Cytometry. COLO 205 cells were synchronized
as previously described [15]. The cells were harvested
at various times with trypsin-EDTA, washed twice with
PBS/0.1%dextrose, and ﬁxedin70%ethanol at4◦C.Nuclear
DNA was stained with a reagent containing propidium
iodide (50μgmL −1) and DNase-free RNase (2 UmL−1)a n d
measured by a ﬂuorescence-activated cell sorter (FACS).
The population of nuclei in each phase of the cell cycle
was determined using the well-known CellFIT DNA analysis
software (Becton Dickenson, San Jose, CA).
2.7. Protein Extraction and Western Blot Analysis. Western
blot analysis was performed as previously described [15,
16]. Immunodetection was carried out by probing with
appropriate dilutions of speciﬁc antibodies at room temper-
ature for 2 h. Anti-p21/Cip1, anti-p27/Kip1, anti-p53, anti-
GAPDHmonoclonal antibodies(SantaC ruz,I nc.,CA,USA)
and anti-cyclin D1, anti-cyclin D3, anti-CDK2, anti-CDK4
and anti-cdc 25C monoclonal antibodies (Transduction
Laboratories, Lexington, KY) were used at a dilution of
1:1000. Anti-cyclin A polyclonal antibodies (Transduction,
San Diego, CA) were used at a dilution of 1:250. The
secondary antibodies, alkaline phosphatase-coupled anti-
mouse and anti-rabbit antibody (Jackson, Westgrove, PA),
were incubated at room temperature for 1h at dilutions of
1:5000 and 1:1000, respectively.
2.8. Analysis of Apoptosis. Apoptosis in COLO 205, HT
29 and FCH cells subjected to the various treatments was
determined by DNA fragmentation analysis [17]. Genomic
DNA was quantiﬁed, and equal amounts of DNA sample
were electrophoresed in a 2% agarose gel. The DNA was
visualized using ethidium bromide staining.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Isolationand chemical structural characterization of SY-1 from AC. (a)HPLC chromatograms of AC. Sample a, fruiting bodies of
AC (YS-187) provided from YushengCo., Ltd (spikedconcentration 20mgmL−1);sampleb, wild fruiting bodies ofAC from Shinyi, Nantou
County in Median Taiwan (spiked concentration 60mgmL−1); and sample c, plate cultivation of fungus A. camphorota (BCRC-36795)
(spiked concentration 20mgmL−1). (b) Chemical structure of 4,7-dimethoxy-5-methyl-l,3-benzodioxole (SY-1).
2.9.SoftAgar Cloning Assay. Thebas ela y erc ons is t edof0.9%
low-gelling point SeaPlaque agarose (Sigma, St Louis, MO)
in complete COLO 205 culture medium. Soft agar consisting
of 0.4% SeaPlaque agarose in complete COLO 205 culture
medium was mixed with 1 × 104 COLO 205 cells and plated
on top of the base layer in a culture dish of 60 mm diameter.
Soft agar cultures were maintained at 37◦Ca n do b s e r v e d
with a Leica DMI 4000B Microscope Imaging System to
evaluate colony counts.
2.10. Statistics. All data are reported as means ± SE.
Comparisons were subjected to one-way analysis of variance
(ANOVA) followed by Fisher’s least signiﬁcant diﬀerence
test. Signiﬁcance was deﬁned as P < .05.
3.Results
3.1. Isolation of SY-1 from AC and Its Structural Characteri-
zation. As seen in Figure 1(a),t h r e ed i ﬀerent sources of AC
were isolated via extensive chromatographic puriﬁcation of
the ethyl acetate-soluble fraction of the dried fruiting body
(Figure 1(a), samples a–c). One major peak was seen for
each sample (indicated as compound 1, C1). The chemical
structure of the puriﬁed white powder (C1) was elucidated
by NMR spectroscopy and mass spectrometry studies and
was identiﬁed as SY-1 (Figure 1(b)).
3.2. Inhibition of Malignant Human Colon Cell Proliferation
by SY-1-Treatment. We examined the eﬀect of SY-1 on the
growth of human cancer cells with various p53 statuses and
on the growth of normal human colonic epithelial cells.
The cells were cultured for 3 days with or without SY-1 (75–
375μM) and were then harvested and counted. Our results
suggest that SY-1 (>150μM P < 5) signiﬁcantly inhibited
cell growth in COLO 205 and HepG2 cells in a dose- and
time-dependent manner (Figures 2(a) and 2(f)). However,
inhibitionofthecancerlinesHT-29,MDA-MB-231andCa9-
22 as well as normal (FHC) cells only occurred at higher
concentrations of SY-1 (>375μM) (Figures 2(b), 2(c), 2(d)
and 2(e)).These resultssuggestthatthewild-type p53cancer
cells were more sensitive to SY-1 treatment than cancer cells
with mutated p53 were.
The yield of SY-1 from dried fruiting body samples
(sample b, BCRC-36795) was 0.415mg g−1.T oe v a l u a t et h e
anti-proliferative eﬀects ofSY-1, isolated from crude extracts
of AC, an equal concentration of SY-1 from AC extracts
was applied to COLO 205 cells and the cytotoxicity assay
wasperformed(Figure 3(a)).Aconcentrationofgreaterthan
150μM SY-1 signiﬁcantly induced cytotoxicity in COLO
205 cells, but lower concentrations had no cytotoxic eﬀects
(Figure 3(a), upper panel). However, signiﬁcant cytotoxic
eﬀects was observed in COLO 205 cells treated with
36mgmL−1 ofAC crudeextractwhichcontainedanidentical
concentration of 75μMS Y - 1( Figure 3(a),l o w e rp a n e l ) .
We next investigated whether the cytotoxic eﬀect of SY-1
on COLO 205 cells was due to apoptotic cell death. SY-
1-induced apoptosis was evaluated by DNA fragmentation
analysis. As shown in Figure 3(b), DNA fragmentation
was only observed in the SY-1-treated COLO 205 cells
(>150μM). In contrast, DNA fragmentation induced by a
higher dose of SY-1 (225μM) was not observed in either the
HT 29 or FCH cells (Figure 3(c)). These results suggest that4 Evidence-Based Complementary and Alternative Medicine
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Figure2: Dose-dependent eﬀects ofSY-1oncellgrowthinmalignantandnormalhumancells.(a)COLO205,(b)HT29,(c)normalhuman
colonicepithelial (FHC), (d) MDA-MB-231,(e) Ca9-22and (f)Hep G2 cells were treated with various concentrations ofSY-1 (75–375μM).
Media with or without SY-1 was renewed daily prior to cell counting. Three samples were analyzed in each group. Values represent mean ±
SE.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3:Dose-dependent SY-1-induced DNA fragmentationinhumancoloncancerandnormalcells. (a)COLO205cells were treated with
SY-1 and AC crude extract in a dose- and time-dependent manner. (b) COLO 205, (c) HT 29 and normal human colonic epithelial (FHC)
cells were treated with SY-1atthe indicated doses.Induction ofapoptosis in all cells wasshownby DNA fragmentationusingelectrophoresis
of genomic DNA. DNA fragmentationwas examined 24 h after drug treatment.
SY-1-induced apoptosis, as observed in the COLO 205 cells,
occurs in a cell-speciﬁc manner.
3.3. Arrest of Cell Cycle at the G0/G1 Phase by SY-1 in Human
COLO 205 Cells. As shown in Figure 2(a), concentrations
of SY-1 ranging from 75 to 350μM induced a dose-
dependent inhibition of cell growth in human COLO 205
cancer cells. We further demonstrated signiﬁcant apoptosis
at doses greater than 150μM( Figure 3(b)). These results
imply that lower doses of SY-1 (<150μM) should aﬀect
the cell cycle. To more clearly demonstrate the actions of
SY-1 during a speciﬁc phase of the cell cycle, the COLO
205 cancer cells were synchronized by switching them to
media that contained 0.04% FCS for 24h to render them
quiescent [15]. Subsequently, the cells were returned to
culture media containing 10% FCS and 0.05% DMSO
with or without 150μM SY-1. The cells were harvested for
ﬂow cytometry analysis of DNA content at various times
thereafter (Figure 4(a)). The results demonstrate that SY-1
induced an accumulation of greater than 85% of COLO 205
cells at the G0/G1 phase of the cell cycle, suggesting that the
observedgrowthinhibitoryeﬀectofSY-1wasduetoanarrest
at the G0/G1 phase of the cell cycle.
Figure 4(b) demonstrates the dose eﬀects of SY-1 on
G0/G1 arrest. According to our previous studies [18, 19]a n d
the representative FACS analysis (Figure 4(a), left panel), 0,
15,21and24hrepresenttheG0/G1,S,G2/Mand2ndG0/G1
phases, respectively. The greatest diﬀerence in the G0/G1
cell populations of the SY-1-treated and control groups was
recorded at 15h after replacement with complete medium.
Accordingly, this time point was selected to study the dose-
dependent eﬀect of SY-1 and to identify the minimal dose of
SY-1 required for induction of G0/G1 arrest, as determined
by ﬂow cytometry analysis. As illustrated in Figure 4(b),
signiﬁcant G0/G1 arrest in COLO 205 cells was induced by
treatment with SY-1 (>50μM) in a dose-dependent man-
ner. We further demonstrated that the Sub-G1 (apoptotic)
population of COLO 205 cells was signiﬁcantly increased by
exposure to more than 150μMS Y - 1f o r1 5h .
3.4. The Eﬀects of SY-1 on G0/G1 Phase Cell-Cycle Regulatory
Proteins. To investigate the underlying molecular mecha-
nisms of SY-1-induced G0/G1 arrest, the COLO 205 cells
were switched to media with 0.04% FCS to render them
quiescent at the G0/G1 phase. They were then returned
to culture media supplemented with 10% FCS and 0.05%6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Time- and dose-dependent SY-1-induced G0/G1 phase arrest and apoptosis in COLO 205 cells. (a) COLO 205 cells were
synchronized with 0.04% FCS for 24 h as described in “Materials and Methods” section. After synchronization, the cells were released
into complete medium (10% FCS) containing 0.05% DMSO (left panel), or 150μM SY-1 in 0.05% DMSO (right panel). The percentages of
cells in theSub-G1, G0/G1,S andG2/M phasesofthecell cyclewere determined usingthewell-knownCellFIT DNAanalysissoftware.Three
samples were analyzed in each group, and values represent the mean ± SE (b). Dose-dependent eﬀects of SY-1 on cell cycle and apoptosis
in human cancer cells. FACS analysis of DNA content 15 h after release from quiescence by incubation in culture media supplemented with
10% FCS and various concentrations of SY-1 in 0.05% DMSO. The percentage of cells in the Sub-G1, G0/G1, S and G2/M phases of the cell
cycle were determined using the CellFIT DNA analysis software. Three samples were analyzed in each group, and values represent the mean
± SE.
DMSO with or without SY-1 (75–225μM). After 15h they
were harvested for protein extraction and western blot
analysis to examine the eﬀects of SY-1 on the expression of
G0/G1 phase cell-cycle regulatory proteins.
Recent studies have demonstrated that the cyclin-
dependent kinase (CDK) inhibitors, including p21/Cip1 and
p27/Kip1, are up-regulated in human cancer cells arrested in
G0/G1 by treatment with anti-cancer agents [20, 21]. Our
previous study showed that the protein levels of p21/Cip1
and p27/Kip1 were increased in the quiescent COLO 205
cells and then decreased 15h after release from quiescence
[22]. Similar results were observed in our present study.
The protein levels of p21/Cip1 and p27/Kip1 were lower at
15h after the addition of 10% FCS medium (Figure 5,r i g h t
panel, lane 1). In contrast, increased p21/Cip1 and p27/Kip1
protein levels were induced in the SY-1 (>70μM)-treated
COLO 205 cells (Figure 5, right panel, lanes 2–4). The levels
of cyclins A, D1 and D3 were down-regulated in the SY-1-
treatedcells,whilethelevelsofCDK2andCDK4proteinsdid
notchange(Figure 5,rightpanel,lanes 2–4).Cdc25C,which
promotes cell entry into the S and the G2/M phases, was also
down-regulated at a higher SY-1 dose (>225μM) (Figure 5,Evidence-Based Complementary and Alternative Medicine 7
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Figure 5: Dose eﬀect of SY-1 on the concentrations of cell-cycle regulatory proteins. Normal human colonic epithelial (FHC, left panel)
and cancer (COLO 205, right panel) cells were rendered quiescent for 24 h and then given 10% FCS in the presence or absence of SY-1 (75–
150μM) for an additional 15h. Protein extracts (100μg/lane) were separated by SDS-PAGE, probed with speciﬁc antibodies and detected
using the nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate systems. Membranes were also probed with an anti-GAPDH
antibody to correct for diﬀerences in protein loading.
right panel, lane 4). As a normal cell control, human FCH
cells were treated with SY-1 at the same concentrations. Our
results show that the cell-cycle regulatory proteins of FCH
cells were substantially less aﬀected than the SY-1-treated
group (Figure 5, left panel).
3.5. P53-Activated Signaling Pathway Is Involved in SY-
1-Induced G0/G1 Arrest. Our previous results show that
signiﬁcant G0/G1 arrest (50–150μM) and apoptosis (above
150μM) were induced by SY-1 in human COLO 205 cancer
cells in the context of wild-type p53 (Figures 3 and 4). In
contrast, SY-1-induced apoptosis was not observed in the
HT 29 (p53 His273 mutant) cells (Figure 3(c),l a n e2 ) .T h e
p53 protein is a potent transcription factor that is involved
in the regulation of cell-cycle arrest and in the induction
of apoptosis [23, 24] .T h ed a t ah e r es u g g e s tt h a tt h ea b i l i t y
of SY-1 to induce human cancer cells to undergo G0/G1
cell-cycle arrest or apoptosis is dependent on the p53 status
of the cells. Interestingly, the level of p53 protein remained
unchanged in the SY-1-treated human colonic epithelial
(FHC) cells (Figure 5). Such observations can explain why
the SY-1-induced antiproliferative eﬀects were tumor cell
speciﬁc (Figure 1). In summary, our results demonstrate
that the levels of p53 and its downstream regulation of
p21/Cip1 and p27/Kip1 proteins were dose-dependently
increased in the SY-1-treated COLO 205 cells. This suggests
that upregulation of p53 and p21/Cip1 might be involved in
SY-1-mediated arrest in these cells.
In contrast to normal adherent cells, tumor cells have the
ability to grow without binding to a substrate. Our data sug-
gests that anchorage-independent proliferation is a hallmark
of tumor cell malignancy [25]. The anchorage-independent
proliferation of COLO 205 cells was investigated in soft
agar colony formation assays (Figure 6). Twelve days after
plating, both the control and SY-1-treated COLO 205 cells
showed colony formation in medium containing 0.3% agar.
As shown in Figure 6(a), the average sizes of the control
COLO 205 colonies were 2-3 times larger than the SY-1-
treated group. Compared to the DMSO-treated control cells,
SY-1 (>75μM) signiﬁcantly reduced the number of colonies
formed in a dose-dependent manner (Figure 6(b),l a n e s2 –
5).
4.Discussion
The present study was undertaken to investigate the anti-
cancer mechanisms of SY-1 isolated from three diﬀerent
sources of dried fruiting bodies from the Chinese medicinal
mushroom,Antrodia camphorate (Figure 7).Previousstudies
have demonstrated that AC induces signiﬁcant apoptotic
cell death in human leukemia (HL-60) [27], breast (MCF-
7 and MDA-MB-231) [27, 28], prostate (LNCaP and PC3)
[29] and liver (Hep G2, C3A and PLC/PRF/5) cancer
cells [2, 30]. Such an eﬀect has never been detected with
cultured human endothelial cells [1]. The anti-proliferative
eﬀects of AC were also reported in diﬀerent types of8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Anchorage-independent growth of SY-1-treated COLO
205 cells in soft-agar. (a) The COLO 205 cells were treated with SY-
1( 7 5μM) following methods described elsewhere [26]. The gross
morphology of COLO 205 cell colonies are shown here on culture
plates. These colonies exhibit subtle changes in their morphology,
including a slight disaggregation compared to the untreated COLO
205cells.Bar=200μM.(b)Thenumberofcoloniesscoredfromthe
soft-agar plates. The COLO 205 cells were seeded in soft agar with
or without SY-1 (75–375μM). The colonies were counted in a 1 ×
3cm 2 area on each plate. Data are the mean ± SE of three diﬀerent
experiments. Signiﬁcancewas accepted at P <.05. Asterisk indicates
that the SY-1-treated groups were signiﬁcantly diﬀerent from the
DMSO-treated group.
human cancer cells including breast [27, 28], prostate [29],
bladder [31], lung [32]a n dh e p a t o m a[ 2]. These results
demonstrate that both cell-cycle inhibition and apoptotic
cell death contribute to the anti-tumor eﬀects of AC.I n
ap r e v i o u sp a p e r[ 33], three puriﬁed compounds were
isolated from AC, namely sesquiterpene lactone (antrocin),
SY-1 and 2,2 ,5,5 -tetramethoxy-3,4,3 4 -bimethylenedioxy-
6,6 -dimethylbiphenyl. To our knowledge, ours is the ﬁrst
demonstration that a puriﬁed compound (SY-1), isolated
from AC, inhibits the cell growth of COLO 205 cells through
arrest of the cell cycle and activation of the cellular apoptotic
response.
In this study, the inhibitory eﬀect of SY-1 on cell growth
appears to be limited to COLO 205 and Hep G2 cells, since
similar eﬀects were not observed in other transformed colon
cancer(HT29)cells(Figure 2).Treatment ofCOLO205cells
with SY-1 resulted in an increase in the levels of p21/Cip1,
p27/Kip1 and p53 proteins, and a decrease in the levels of
cyclins A, D1 and D3 (Figure 5). Among these changes, p53
seems to have a major role in SY-1-induced G0/G1 arrest
in COLO 205 cells (Figure 7) .I ts e e m st h a tS Y - 1e x e r t si t s
anti-tumor activity through cell-cycle arrest or activation
of the cellular apoptotic response, depending on the p53
status. A previous report demonstrated that HT-29 cells
contain a point mutation at codon 273 (Arg→His) of the
p53 gene [8], making it a less eﬃcient inducer of apoptosis
[34]. On the other hand, over-expression of mutant p53 is
a common theme in human tumors, suggesting a tumor-
promoting gain-of-function associated with mutant p53
[35]. A recent study demonstrated that knockdown of
mutant p53 sensitizes human colon tumor cells to growth
suppression under the activity of various chemotherapeutic
drugs [35]. Such results suggest that COLO 205 cells that
contain wild-type p53 are susceptible to SY-1-mediated
anti-tumor eﬀects. Moreover, SY-1-induced G0/G1 cell-
cycle regulatory proteins did not change signiﬁcantly in the
normal colonic cells, namely FHC (Figure 5, left panel).
Additionalsignals, otherthanp53,may beinvolvedin COLO
205, but are not involved with FHC cells.
Human colonic cancer cells often respond in only a
limited manner to the currently available chemotherapeutics
due to the expression of multidrug resistance genes [36].
Indeed, humancancercellswith mutantp53seem toactivate
the promoters of genes that are not usually activated by
wild-type p53 protein, such as multidrug resistance gene
1 (MDR1) and c-MYC [37]. Such results suggest that
combination therapy is one potential strategy for reducing a
compound’s undesirable toxic eﬀect while still maintaining
or enhancing its anti-tumor eﬃcacy. In the present study,
our results demonstrate that SY-1 inhibits colonic cancer cell
growth in the G0/G1 phase, induces apoptosis and inhibits
colony formation in COLO 205, but not in HT 29 cells.
Recent epidemiologic and laboratory investigations suggest
that aspirin and other nonsteroidal anti-inﬂammatory drugs
(NSAIDs) exhibit chemopreventive eﬀects against colon
cancer, perhaps due, at least in part, to their activity against
cyclooxygenase-2 (COX-2) [38]. In addition, induction of
apoptosis by AC, through inhibition of COX-2, has also
been reported in human breast cancer cells (MDA-MB-231)
[27]. In vivo studies have demonstrated that AC extract
treatment of human hepatoma cells (C3A and PLC/PRF/5)
inhibits MDR gene expression and the pathway of COX-2-
dependent inhibition of p-AKT to induce apoptosis [2]. To
our knowledge, COX-2 is strongly expressed in all metastatic
cell lines (HT-29) but not in non-metastatic lines (COLO
205) [39]. These results imply that AC-mediated COX-2
inhibition is important for inhibition of colon cancer cell
growth. However, our results demonstrate that inhibition of
cell growth in the HT 29 cells was less profound than in
COLO 205 cells (Figure 2), indicating that SY-1, although
isolated from AC, may not exert its anti-tumor eﬀects
completely through the inhibition of COX-2. In summary,
although animal studies of SY-1-induced anti-tumor activityEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: Schematicdiagram ofsignalingpathways involved inSY-1-induced cell-cycle arrest and apoptosisin humanCOLO205 cells. SY-1
was isolated from the fruiting body of AC (upper left). After treatment with SY-1, the p53-regulated p21/p27 signals in COLO 205 cells
resulted in inhibition of soft agar colony formation.
are still ongoing, the ﬁndings from the present in vitro study
suggest the potential applications of SY-1 in the treatment
of human cancer. The universality of SY-1 in the inhibition
of cancer cell proliferation makes it an attractive agent for
chemotherapy.
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